RAAS is a blood products manufacturer in China with high comprehensive utilization of plasma raw materials and is engaged in the research, development, and manufacture of blood products and plasma-derived medical products. China accounts for 96.6% of net sales, providing strong domestic market penetration. The company made a merger/acquisition deal with Nanyue Biopharming on March 26, 2025, signaling growth through consolidation.
Cyborg Score Rationale
RAAS holds a market cap of approximately $6.4B with trailing 12-month revenue of $1.09B as of mid-2025, demonstrating solid scale and profitability in the niche plasma-derived therapeutics market. The company has strong domestic market dominance and strategic M&A activity. However, GuruFocus has flagged 3 severe warning signs, suggesting operational or financial concerns requiring monitoring.
Top Insights
Dominant player in Chinese blood products market with 37-year operating history and established distribution network
Recent M&A activity with Nanyue Biopharming (March 2025) suggests aggressive growth and consolidation strategy
GuruFocus has identified 3 severe warning signs that require investigation despite solid fundamentals
High domestic revenue concentration (96.6% from China) indicates limited international diversification but strong domestic moat
Named Competitors
Grifols — Global plasma-derived therapeutics manufacturer
CSL Limited — Major international blood products producer
China Biologic Products — Domestic Chinese blood products competitor
Recent Developments
(March 2025) Merger/acquisition deal with Nanyue Biopharming completed
(November 2025) Stock trading at CNY 6.89 with mixed analyst sentiment (2 buy, 1 sell recommendation)
Open the full interactive Shanghai RAAS Blood Products Co., Ltd. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.